Monday, February 18, 2019 1:57:55 PM
Pourhassan's salary and benefit package is akin to what a top level CEO of a highly profitable company, with a long track record of success, could expect to receive.
I am not aware of any CEO in a fledgling clinical stage biopharma such as Cytodyn that has received anything close to the salary and compensation package Pourahassan has been taking for many years. Most such CEO's take a minimal salary, and receive most of their compensation in the form of options or warrants.
Pourhassan does not have the background or experience to justify the exorbitant salary he has been taking for many years even if the company was profitable. However, to continue to take an exoribitant salary, without purchasing one share of stock, and while the company continues to bleed money, is outrageous.
I have a big stake in Cytodyn, through numerous Paulson raises (without thereafter selling my stock and holding the warrants, most of which have now expired worthless), and truly want the company to succeed. However, as a significant shareholder, I deeply resent so much of my money being paid to a CEO who is clearly undeserving of being compensated so lavishly.
LM
I am not aware of any CEO in a fledgling clinical stage biopharma such as Cytodyn that has received anything close to the salary and compensation package Pourahassan has been taking for many years. Most such CEO's take a minimal salary, and receive most of their compensation in the form of options or warrants.
Pourhassan does not have the background or experience to justify the exorbitant salary he has been taking for many years even if the company was profitable. However, to continue to take an exoribitant salary, without purchasing one share of stock, and while the company continues to bleed money, is outrageous.
I have a big stake in Cytodyn, through numerous Paulson raises (without thereafter selling my stock and holding the warrants, most of which have now expired worthless), and truly want the company to succeed. However, as a significant shareholder, I deeply resent so much of my money being paid to a CEO who is clearly undeserving of being compensated so lavishly.
LM
Recent CYDY News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
